NCT07870707Not yet recruiting
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Prostate Cancer Retrospective Prevalence, Screening, Outcome Data in NHS-served Prisons UK (PRISON-UK)
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early stage. However, people in prison face significant barriers to healthcare, and little is known about how prostate cancer affects this population. This is concerning, as the prison population is ageing, and men over 50 are at the highest risk of developing prostate cancer. Research shows that prisoners are more likely to be diagnosed with any cancer at a late stage, often through emergency hospital visits, and are less likely to receive timely or curative treatment compared to the general population. Survival rates are also worse. However, there are very little data from the UK describing prostate cancer diagnosis and outcomes in the UK from the prison population, which this study aims to address and compare to a non-prison control group. This project, a collaboration between Oxleas NHS Trust and The Royal Marsden, will test and develop processes for extracting pseudo-anonymised data from the prison population. Using pseudo-anonymous data from prisoner health records in Oxleas NHS Trust, the Research Team will assess prevalence and examine how prostate cancer is diagnosed, the treatments offered, and the survival outcomes. Comparison will be made between the prison findings against UK Genetic Prostate Cancer Study (UKGPCS) data about men of a similar age in the non-prison population. Our aim is to understand whether prisoners face delays in diagnosis and worse outcomes, and to assess whether prison-based screening could help. The findings will inform future healthcare research and the development of policies and may support the development of tailored educational resources and screening approaches, ultimately helping to reduce health inequalities and improve outcomes for people in prison.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 9007 (estimated)
- First submitted
- 6 Oct 2026
- Start date
- 3 Dec 2026
- Primary completion date
- 3 Aug 2027
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Diseases
- Prostate cancer
- NCT number
- NCT07870707
What you commit to
- Study type: Observational
- Planned participants: 9007
- From 3 Dec 2026 to the primary completion date, 3 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individual cases will be excluded if it is found that a diagnosis of prostate cancer was not received, even if they underwent extensive investigations for prostate cancer.
Other illness
- Although the number of prisoners living with a diagnosis of prostate cancer will be noted, those who were diagnosed with prostate cancer outside of their prison stay will not undergo further data extraction for data around diagnosis and outcomes.
Other
- Potential participants who have opted out via the NHS England National Data Opt-Out (NDOO) service and therefore their data will not be used.
Who the study is looking for
- Pseudo-anonymous data from prostate cancer code-search in the digital health records of:
- Adult men (over 18 years of age) and people with prostates in the UK prison population with healthcare under Oxleas NHS Trust (sample includes 13 prisons under Oxleas NHS Trust with 9,007 adult men).
- Full data extraction will only occur for prisoners who have been diagnosed with prostate cancer while in the custody of His Majesty's Prison Service. The number of prisoners living with a diagnosis of prostate cancer will be noted, but no further data extraction will take place if diagnosed outside of prison.
- Prostate cancer diagnosis may be made clinically (based on symptoms, PSA levels and clinical examination) or confirmed with histology. Core data that ideally should be available for inclusion are:
- age at diagnosis
- method of diagnosis (screening/ 2WR (symptomatic)/ emergency),
- PSA at diagnosis
- prostate cancer stage at diagnosis.
- The prisoners may or may not have another primary cancer at time of diagnosis, however the prostate cancer itself must also be a prostate primary.
- Records will be searched as far back as the Oxleas Data Team will be able to search electronic health records.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Marsden NHS Foundation Trust Coordinator of this site? Confirm its status | Sutton | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.